SCHEMBL2152907

SCHEMBL2152907

O=C(O)C(=Cc1ccccc1Br)NC(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.44
HDAC3 O15379 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
IDO1 P14902 1/20 0.43
ALOX15 P16050 1/20 0.43
HDAC1 Q13547 1/20 0.43
CA9 Q16790 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NCOR2 Q9Y618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2152897 0.83 HSD11B1 (0.46) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2152900 0.83 HSD11B1 (0.46) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2153340 0.81 MEN1 (0.47) MAPTMEN1KMT2ASMN1; SMN2PKM
SCHEMBL5895586 0.80 ALDH1A1 (0.48) MAPTMEN1KMT2ASMN1; SMN2PKM
SCHEMBL5895612 0.80 ALDH1A1 (0.48) MAPTMEN1KMT2ASMN1; SMN2PKM
SCHEMBL5895599 0.80 ALDH1A1 (0.48) MAPTMEN1KMT2ASMN1; SMN2PKM
SCHEMBL1942388 0.78 MAPT (0.57) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7112204 0.78 MAPT (0.57) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1942389 0.78 MAPT (0.57) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4688334 0.78 LMNA (0.52) MAPTKMT2ASMN1; SMN2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833789-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID DSM IP ASSETS BV (NL) 2011-07-06 EP disclosed
US-7732621-B2 Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid DSM IP ASSETS B.V. (NL) 2010-06-08 US disclosed
US-20090043112-A1 Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid DSM IP ASSETS B.V. (NL) 2009-02-12 US disclosed
EP-1833789-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID DSMIP Assets B.V. (NL) 2007-09-19 EP disclosed
WO-2006069799-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID DSM IP ASSETS B.V. (NL) 2006-07-06 WO disclosed
EP-1676838-A1 Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid DSM IP Assets B.V. (NL) 2006-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090043112-A1 Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid IDO2, IDO1, KYNU MAPT 215/4885MEN1 3646/4885KMT2A 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.